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Abstract
In every human being, there is a substantial proportion (1–2 kg) of total body weight constituted by the gut micro-
biota content in the gastro-intestinal system. Recent research findings, based on mapping of the microbiome, have 
stated that in healthy subjects, the gut microbiota richness and diversity is higher as compared to obese subjects or 
patients suffering from cardiometabolic disease, or even long-standing hypertension when a different and less rich 
pattern is seen (dysbiosis). Intervention with certain food constituents, e.g. Mediterranean diet or dairy products 
such as lactobacillae-containing yoghurt, holds promise that this could be of benefit for improved organ function, 
improved metabolism and lowering disease risk. Randomized, controlled intervention studies are needed to test the 
hypothesis that a reduction in dysbiosis induced by external dietary interventions could translate into health benefits.
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In cardiovascular epidemiology, the major tradi-
tional risk factors have been known for decades (hy-
pertension, hyperlipidemia, smoking, diabetes), but 
in later years the interest grew for new risk markers 
such as insulin resistance, chronic inflammation, 
albuminuria and the metabolic syndrome, just to 
name a  few. These risk factors act on increasing 
pathophysiological processes leading to target organ 
damage (TOD) that is measurable as the conse-
quence of the risk burden during many years, such 
as left ventricular hypertrophy (LVH), arterial stiff-
ness (increased pulse wave velocity, PWV), micro-
albuminuria and white matter lesions in the central 
nervous system. Modern guidelines on cardiovas-
cular prevention have tried to discuss the practical 
implications of these risk factors and corresponding 
complications [1, 2].
A positive family history of cardiovascular disease 
is a component of all these guidelines and a widely 
studied factor for increased risk, especially if there is 
early onset of disease manifestations in first-degree 
relatives or other close family members [3]. The 
epidemiological background is that a  number of 
chronic disease conditions tend to cluster in fami lies 
with an increased risk in first-degree relatives, but 
also an increased risk in second-degree relatives [4]. 
This fact is most often referred to as the heritability 
(heredity) of these diseases and explained by the 
influence of genetic factors transferred across gen-
erations, or shared environment, even if the more 
specific details or mechanisms leading to disease are 
not known. In clinical medicine, a positive family 
history is often asked about during consultations, 
but the information provided is sometimes not ex-
act, due to unawareness, poor recollection of data or 
other factors which bias the answers. Therefore, new 
methods have to be explored in screening studies 
and register linkage studies to define and measure 
consequences of a positive family history of disease. 
Furthermore, recent studies have indicated that dif-
ferent genetic scores of well-known genetic risk 
markers of disease conditions such as obesity, type 2 
diabetes or myocardial infarction are only able to 
explain a minor proportion of this described heri-
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tability [5]. Thus, there is still a lack of knowledge 
to explain the so-called “missing heritability” of 
these disorders. One model for understanding this 
is that gene-environmental interactions and epi-
genetics will add information to explain the hered-
itability, besides influences of shared environment 
in a broader sense. This is still not a well-researched 
area, which is why there is a need of more and bet-
ter quality information from both populations and 
families on genetic profiling (genotyping) as well 
as on bodily function (phenotyping) and data on 
lifestyle and environmental exposures. Of special 
relevance is to elucidate on genetic and non-genetic 
mechanisms behind early cardiovascular and meta-
bolic ageing [6], as a model for early disease onset 
within risk families. These associations are now be-
ing investigated in the ongoing Malmö Offspring 
Study (www.med.lu.se/mos) in southern Sweden, 
including genetic mapping as well as advanced 
phenotyping across three generations. In addition, 
a 4-day dietary registration is being carried out, by 
use of a web-form as well as by other methods.
The gut microbiota pattern in health and 
disease
Of particular interest is to determine the role of 
the microbiome, measured as microbiota pattern (the 
gut bacteria composition and diversity, but also from 
the oral cavity), and its association with dietary intake 
together with the genetic profile of the host, in rela-
tion to alterations in metabolism, obesity, hyperten-
sion, vascular function and immunological function 
[7–10]. This will be linked to other research areas in 
microbiology, nutritional sciences, technology, and in-
novation for prevention. For example, functional food 
products can be developed and tailored to match the 
profile and needs of the individual based on a more 
detailed personal profiling, for example the nutri-
tion-gene-microbiota mapping (stratified medicine).
A  remarkable finding in a  family perspective is 
that the microbiome of individuals is influenced in 
early life, in the first place by the microbiota of the 
mother from exposure to the offspring during vagi-
nal delivery and during the neonatal period [11]. 
Later on, this is influenced by more or less shared 
microbiota patterns in the family household during 
childhood and adolescence due to cohabitation. It is 
hypothesized whether microbiota profile as well as 
dietary intake patterns may cluster within families. 
This pattern is likely to change temporarily, following 
travelling abroad or treatment periods with antibio-
tics, but may return after some time to the previous 
(programmed) pattern.
Biomarkers of diet-microbiota patterns 
may predict future cardiovascular 
outcomes
Recently, it has been discovered that there is also 
a  specific serum biomarker, the pro-atherosclero-
tic metabolite, trimethylamine-N-oxide (TMAO) 
that is able to reflect the gut microbiome and pre-
dict cardiovascular events in healthy subjects [12]. 
TMAO can also predict prognosis in patients with 
congestive heart failure, thus influencing clinical 
prognosis [13]. Interventions to change the mi-
crobiota have provided promising results [14] and 
been described as a potential new treatment target 
for cardio-metabolic disease. Such interventions 
should be based on the wider use of designed and 
tested functional food products as part of a healthy 
lifestyle in general. This provides an ultimate test 
on the causality linking microbiota patterns and 
disease and whether this association is reversible or 
not following interventions.
Microbiota patterns in subjects with 
hypertension
The microbiota pattern in association with hyper-
tension has been documented in both hypertensive 
animal models [15] as well as in human hyperten-
sives [16, 17]. In one of the best studies so far, bac-
terial DNA from fecal samples of two rat models of 
hypertension and a small cohort of hypertensive pa-
tients, was used for bacterial genomic analysis [16]. 
The authors observed a  significant decrease in 
microbial richness, diversity, and evenness in the 
spontaneously hypertensive rat, in addition to an 
increased Firmicutes/Bacteroidetes ratio. In addition, 
the microbiota of a  small cohort of human hy-
pertensive patients was found to follow a  similar 
dysbiotic pattern, as it was less rich and diverse 
than that of control subjects, and with a microbiota 
pattern not overlapping that of the normotensive 
controls. Similar changes in gut microbiota were 
observed in the chronic angiotensin II infusion rat 
model, most notably decreased microbial richness 
and an increased Firmicutes/Bacteroidetes ratio. In 
this lab model, the efficacy of an oral antibiotic drug 
(minocycline) in restoring gut microbiota was also 
tested. In addition to attenuating high blood pres-
sure, minocycline treatment was able to rebalance 
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the dysbiotic hypertension gut microbiota by re-
ducing the Firmicutes/Bacteroidetes ratio. Thus, these 
observations clearly demonstrated that high blood 
pressure is associated with gut microbiota dysbiosis, 
both in animal and human hypertension [16]. How-
ever, larger studies are needed, as well as inclusion of 
hypertensive patients of different disease duration 
and prevalence rates of TOD.
Could gut microbiota patterns be 
favorably intervened on?
Different dietary interventions influencing gut 
microbiota have been tried in hypertension. One me-
ta-analysis could show that increased intake of dairy 
products, including lactobacillae-containing yoghurt, 
is associated with a reduced tendency to develop hy-
pertension during the follow-up period [18].
In another study, it was shown that blueberries fer-
mented with the tannase-producing bacteria L. plan-
tarum DSM 15313 have anti-hypertensive properties 
and may reduce the risk for cardiovascular diseases [19].
Finally, the anti-inflammatory properties of the 
Mediterranean diet could be another mode of action 
to explain the health benefits and cardiovascular pre-
vention possible to achieve with implementing this 
diet [20], a link that has been proposed to change gut 
microbiota patterns for the better [21]. In this per-
spective, there seems to exist a considerable potential 
for dietary modifications influencing gut microbiota 
composition and facilitating health [22].
Summary
In summary, the family clustering of cardiometa-
bolic disorders is a well-known clinical observation, 
but still not fully understood. Genetic factors, even 
put together in a genetic risk score, can explain just 
a minor proportion of the increased family risk. New 
discoveries linking gut microbiota to obesity, type 2 
diabetes and cardiometabolic risk conditions could 
explain some of this increased clustering. Gut micro-
biota could potentially be influenced by functional 
food products, probiotics and healthy lifestyle, pro-
viding a  link to cardiovascular and metabolic pre-
vention. The Mediterranean diet could be of special 
importance for health benefits and its associations to 
the gut microbiota patterns should be explored. In 
a similar way the health aspects, as mediated by gut 
microbiota influences, of pickled vegetables (“kapus-
ta”) rich in lactobacillae as well as dairy products such 
as natural yoghurt should be further explored.
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